EIF2B5 and liver cancer: In addition, dysregulated EIF2B5 expression was also corrected with the progression of liver cancer (Jiao et al. 2018), colorectal cancer (Palaniappan et al. 2016) and diffuse large B-cell lymphoma (Unterluggauer et al. 2018).